Cyclin D1 is one of the drivers of the cell cycle, and its deregulation may promote the development of tumours. Surprisingly, this protein also mediates the repair of damaged DNA, a mechanism that commonly prevents cancer. See Letter p.230
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
EGFL6 promotes colorectal cancer cell growth and mobility and the anti‐cancer property of anti-EGFL6 antibody
Cell & Bioscience Open Access 16 March 2021
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Jackson, S. P. & Bartek, J. Nature 461, 1071–1078 (2009).
Sherr, C. J. & Roberts, J. M. Genes Dev. 18, 2699–2711 (2004).
Jirawatnotai, S. et al. Nature 474, 230–234 (2011).
Mazón, G., Mimitou, E. P. & Symington, L. S. Cell 142, 646 (2010).
Bartek, J. et al. Curr. Opin. Cell Biol. 8, 805–814 (1996).
Jensen, R. B., Carreira, A. & Kowalczykowski, S. C. Nature 467, 678–683 (2010).
Thorslund, T. et al. Nature Struct. Mol. Biol. 17, 1263–1265 (2010).
Hoeijmakers, J. H. J. Nature 411, 366–374 (2001).
Halazonetis, T. et al. Science 319, 1352–1355 (2008).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bartek, J., Lukas, J. Cyclin D1 multitasks. Nature 474, 171–172 (2011). https://doi.org/10.1038/474171a
Published:
Issue Date:
DOI: https://doi.org/10.1038/474171a
This article is cited by
-
Jug-PLGA-NPs, a New Form of Juglone with Enhanced Efficiency and Reduced Toxicity on Melanoma
Chinese Journal of Integrative Medicine (2022)
-
EGFL6 promotes colorectal cancer cell growth and mobility and the anti‐cancer property of anti-EGFL6 antibody
Cell & Bioscience (2021)
-
Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
Cancer Chemotherapy and Pharmacology (2017)
-
MEK drives cyclin D1 hyperelevation during geroconversion
Cell Death & Differentiation (2013)